Adaptimmune Therapeutics PLC Company Profile (NASDAQ:ADAP)

About Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADAP
  • CUSIP: N/A
  • Web: www.adaptimmune.com
Average Prices:
  • 52 Week Range: $3.76 - $8.89
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.91
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -550.22%
  • Return on Equity: -41.40%
  • Return on Assets: -32.32%
Debt:
  • Current Ratio: 6.99%
  • Quick Ratio: 6.99%
Misc:
  • Average Volume: 217,959 shs.
  • Beta: 1.26
 
Frequently Asked Questions for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

What is Adaptimmune Therapeutics PLC's stock symbol?

Adaptimmune Therapeutics PLC trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics PLC's earnings last quarter?

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.06. The firm had revenue of $2.86 million for the quarter, compared to analyst estimates of $5.07 million. Adaptimmune Therapeutics PLC had a negative net margin of 550.22% and a negative return on equity of 41.40%. View Adaptimmune Therapeutics PLC's Earnings History.

Where is Adaptimmune Therapeutics PLC's stock going? Where will Adaptimmune Therapeutics PLC's stock price be in 2017?

5 equities research analysts have issued twelve-month target prices for Adaptimmune Therapeutics PLC's shares. Their forecasts range from $15.00 to $16.00. On average, they anticipate Adaptimmune Therapeutics PLC's share price to reach $15.50 in the next twelve months. View Analyst Ratings for Adaptimmune Therapeutics PLC.

What are analysts saying about Adaptimmune Therapeutics PLC stock?

Here are some recent quotes from research analysts about Adaptimmune Therapeutics PLC stock:

  • 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells." (6/6/2017)

Who are some of Adaptimmune Therapeutics PLC's key competitors?

Who are Adaptimmune Therapeutics PLC's key executives?

Adaptimmune Therapeutics PLC's management team includes the folowing people:

  • James Julian Noble, Chief Executive Officer, Director
  • Adrian Rawcliffe, Chief Financial Officer
  • William C. Bertrand Jr., J.D., Chief Operating Officer
  • Gwendolyn Binder-Scholl Ph.D., Chief Technology Officer
  • William Roberts, Vice President of Investor Relations
  • Rafael Amado M.D., Chief Medical Officer
  • Helen Katrina Tayton-Martin Ph.D., Chief Business Officer
  • David M. Mott, Non-Executive Chairman of the Board
  • Lawrence M. Alleva, Non-Executive Independent Director
  • Ali Behbahani M.D., Non-Executive Independent Director

When did Adaptimmune Therapeutics PLC IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who owns Adaptimmune Therapeutics PLC stock?

Adaptimmune Therapeutics PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (12.86%) and Creative Planning (0.00%). Company insiders that own Adaptimmune Therapeutics PLC stock include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Institutional Ownership Trends for Adaptimmune Therapeutics PLC.

How do I buy Adaptimmune Therapeutics PLC stock?

Shares of Adaptimmune Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adaptimmune Therapeutics PLC's stock price today?

One share of Adaptimmune Therapeutics PLC stock can currently be purchased for approximately $5.35.


MarketBeat Community Rating for Adaptimmune Therapeutics PLC (NASDAQ ADAP)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  114
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $15.50 (189.72% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/6/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/17/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$15.00N/AView Rating Details
10/24/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
9/30/2016Raymond James Financial, Inc.Initiated CoverageOutperform$16.00N/AView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyN/AView Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00N/AView Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$16.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Earnings by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Earnings History by Quarter for Adaptimmune Therapeutics PLC (NASDAQ ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/20173/31/2017($0.24)($0.30)$5.07 million$2.86 millionViewN/AView Earnings Details
3/13/201712/31/2016($0.27)($0.22)$3.98 million$8.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.27)($0.24)($0.26)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.27)($0.25)($0.26)
Q4 20172($0.29)($0.25)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Insider Ownership Percentage: 24.45%
Institutional Ownership Percentage: 56.16%
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2017Enterprise Associates 14 NewMajor ShareholderBuy12,870,000$0.70$9,009,000.00View SEC Filing  
3/27/2017Orbimed Advisors LlcDirectorBuy1,190,476$4.20$4,999,999.20View SEC Filing  
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Latest Headlines for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Source:
DateHeadline
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 2:16 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - July 21 at 12:44 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 9:40 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Expected to Announce Quarterly Sales of $5.43 Million
www.americanbankingnews.com - July 13 at 9:18 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - July 11 at 8:24 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - July 8 at 9:32 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - June 27 at 2:39 PM
americanbankingnews.com logo Brokerages Anticipate Adaptimmune Therapeutics PLC (ADAP) Will Announce Quarterly Sales of $5.43 Million
www.americanbankingnews.com - June 17 at 7:58 AM
americanbankingnews.com logo Analysts Expect Adaptimmune Therapeutics PLC (ADAP) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - June 15 at 8:22 PM
nasdaq.com logoEuropean ADRs Move Higher in Wednesday Trading
www.nasdaq.com - June 14 at 8:21 PM
prnewswire.com logoBioLife Solutions Executes Supply Agreement with Adaptimmune for ... - PR Newswire (press release)
www.prnewswire.com - June 14 at 3:20 PM
reuters.com logoBRIEF-Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
www.reuters.com - June 14 at 8:44 AM
bizjournals.com logoBioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
www.bizjournals.com - June 14 at 8:44 AM
bizjournals.com logoEwing Sarcoma Pipeline Analysis by Stage of Development, Drug Target and Molecule Type New Report Available at RnRMarketResearch.com
www.bizjournals.com - June 13 at 3:20 PM
seekingalpha.com logoAdaptimmune Therapeutics (ADAP) Presents At American Society Of Clinical Oncology 2017 Annual Meeting - Slideshow
seekingalpha.com - June 8 at 8:25 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO ... - StreetInsider.com
www.streetinsider.com - June 6 at 3:32 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - June 6 at 1:40 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO Meetings
www.streetinsider.com - June 5 at 1:28 PM
reuters.com logoBRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
www.reuters.com - June 5 at 1:28 PM
finance.yahoo.com logoAdaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 5 at 1:28 PM
finance.yahoo.com logoAdaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:52 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 2 at 7:40 AM
globenewswire.com logoAdaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 28 at 3:18 PM
reuters.com logoBRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells
www.reuters.com - May 27 at 3:22 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Begins Study to Evaluate ... - StreetInsider.com
www.streetinsider.com - May 26 at 3:26 PM
globenewswire.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with ... - GlobeNewswire (press release)
globenewswire.com - May 26 at 3:25 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Announces an Oral Presentation and Four Trials in Progress Posters at ASCO - StreetInsider.com
www.streetinsider.com - May 26 at 3:25 PM
globenewswire.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T ... - GlobeNewswire (press release)
globenewswire.com - May 25 at 3:36 PM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
finance.yahoo.com - May 25 at 3:36 PM
reuters.com logoBRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy
www.reuters.com - May 16 at 8:20 PM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
finance.yahoo.com - May 16 at 3:20 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - Forecasted to Earn Q2 2017 Earnings of ($0.24) Per Share (ADAP)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Announces Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 11 at 5:12 PM
reuters.com logoBRIEF-Adaptimmune Q1 loss per share $0.05
www.reuters.com - May 10 at 8:26 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell ... - StreetInsider.com
www.streetinsider.com - May 10 at 3:26 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
www.streetinsider.com - May 10 at 9:36 AM
finance.yahoo.com logoAdaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
finance.yahoo.com - May 10 at 9:36 AM
finance.yahoo.com logoAdaptimmune Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 9:36 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 8 at 10:08 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:15 AM
finance.yahoo.com logoAdaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
finance.yahoo.com - May 3 at 8:28 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earns Coverage Optimism Rating of 0.03
www.americanbankingnews.com - May 3 at 8:30 AM
finance.yahoo.com logoAdaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference - Yahoo Finance
finance.yahoo.com - May 3 at 6:45 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Getting Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 11:18 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Adaptimmune Therapeutics PLC - (ADAP) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - April 28 at 12:48 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earning Somewhat Negative Media Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 9:32 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Earning Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 8:19 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC - (ADAP) Receives Daily News Impact Score of 0.56
www.americanbankingnews.com - April 15 at 8:23 AM
nasdaq.com logoAdaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering - Nasdaq
www.nasdaq.com - April 11 at 8:25 AM

Social

Chart

Adaptimmune Therapeutics PLC (ADAP) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff